Type 1 Diabetes – Epidemiology Forecast to 2029

Type 1 Diabetes (T1D), formerly referred to as insulin-dependent diabetes, is a type of diabetes that predominantly develops in children or young adults before the age of 40 years. The condition, therefore, was also referred to as juvenile diabetes. T1D accounts for about 5-10% of all diabetes cases and occurs as a result of the autoimmune destruction of pancreatic beta cells, which are responsible for producing insulin, a hormone that regulates blood sugar. If the condition is left untreated, blood sugar levels accumulate. In addition to the pancreas, high levels of blood sugar can damage other major organs such as the heart, blood vessels, nerves, eyes, and kidneys. Such damage can be life threatening; thus, T1D has an immense impact on the physical, psychological, and social well-being of patients. Furthermore, research suggests that the incidence of T1D is increasing globally, which may lead to an increased burden on healthcare resources (Holt, 2004; World Health Organization, 2013; Mayo Clinic, 2020).

In the 8MM, the diagnosed prevalent cases of T1D will increase from 3,329,294 cases in 2019 to 3,921,695 cases in 2029, at an Annual Growth Rate (AGR) of 1.78% per year. Among the 8MM, the US had the highest number of diagnosed prevalent cases of T1D in 2019 and 2029, at 1,719,922 cases and 1,880,013 cases, respectively. Canada had the lowest number of prevalent cases of T1D in 2019 and 2029, at 146,616 cases and 202,325 cases, respectively. GlobalData epidemiologists attribute the increase in the diagnosed prevalent cases of T1D in the 8MM to population changes as well as an increased trend in prevalence. However, further research is necessary to clearly understand the epidemiological factors responsible for the growth in the prevalent cases of T1D (Onkamo et al., 1999).

Scope

Type 1 Diabetes (T1D) Epidemiology Report and Model provides an overview of the risk factors, comorbidities, and the global and historical trends for T1D in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada). Additionally, the report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of T1D segmented by age (ages under 20 years, 20-29 years, 30-44 years, 45-59 years, 60-74 years, and 75 years and older), sex, body mass index (BMI), brittle (difficult-to-control) diabetes, experienced a diabetic ketoacidosis event, experienced hypoglycemia events, eligible for pancreas and/or islet transplantation, and require/will undergo a kidney transplant or have already received a kidney transplant. The report also includes total prevalent cases of T1D for all ages and both sexes. To forecast the diagnosed prevalent cases of T1D in the 8MM, GlobalData epidemiologists selected nationally representative population-based studies that provided data for the diagnosed prevalence of T1D in the 8MM.

The T1D epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The T1D Epidemiology series will allow you to:

Develop business strategies by understanding the trends shaping and driving the global T1D market.

Quantify patient populations in the global T1D market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups that present the best opportunities for T1D therapeutics in each of the markets covered.

Understand magnitude of T1D by BMI, brittle diabetes, diabetic ketoacidosis event, and hypoglycemia events.

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 T1D: Executive Summary

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Diagnosed Prevalent Cases of T1D

3.4.3 Diagnosed Prevalent Cases of T1D by Body Mass Index

3.4.4 Diagnosed Prevalent Cases of T1D with Brittle Diabetes

3.4.5 Diagnosed Prevalent Cases of T1D Experienced with Diabetic Ketoacidosis Event

3.4.6 Diagnosed Prevalent Cases of T1D Who Experienced Hypoglycemia Events

3.4.7 Diagnosed Prevalent Cases of T1D Who Are Eligible for Pancreas and/or Islet Transplantation

3.4.8 Diagnosed Prevalent Cases of T1D Who Require/Will Undergo a Kidney Transplant or Have Already Received a Kidney Transplant

3.4.9 Total Prevalent Cases of T1D

3.5 Epidemiological Forecast for T1D (2019-2029)

3.5.1 Diagnosed Prevalent Cases of T1D

3.5.2 Age-Specific Diagnosed Prevalent Cases of T1D

3.5.3 Sex-Specific Diagnosed Prevalent Cases of T1D

3.5.4 Diagnosed Prevalent Cases of T1D by BMI

3.5.5 Diagnosed Prevalent Cases of T1D with Brittle Diabetes and Diabetic Ketoacidosis Event

3.5.6 Diagnosed Prevalent Cases of T1D Who Have Experienced Hypoglycemia Events

3.5.7 T1D Diagnosed Patients Who Are Eligible for Pancreas and/or Islet Transplantation and Who Require/Will Undergo a Kidney Transplant OR Have Already Received a Kidney Transplant

3.5.8 Total Prevalent Cases of T1D

3.6 Discussion

3.6.1 Epidemiological Forecast Insight

3.6.2 COVID-19 Impact

3.6.3 Limitations of the Analysis

3.6.4 Strengths of the Analysis

4 Appendix

4.1 Bibliography

4.2 Primary Research – Prescriber Survey

4.3 Abbreviations

4.4 About the Authors

4.4.1 Epidemiologist

4.4.2 Reviewers

4.4.3 Global Director of Therapy Analysis and Epidemiology

4.4.4 Global Head and EVP of Healthcare Operations and Strategy

4.5 About GlobalData

4.6 Contact Us

4.7 Disclaimer

List of Tables

Table 1: Summary of Newly Added Data Types and Countries

Table 2: Summary of Updated Data Types

Table 3: Risk Factors and Comorbidities for T1D

Table 4: High-Prescribing Physicians (KOL and non-KOLs) Surveyed, By Country

List of Figures

Figure 1: 8MM, Diagnosed Prevalent Cases of T1D, All Ages, Both Sexes, N, 2019 and 2029

Figure 2: 8MM, Diagnosed Prevalence (%) of T1D, Men, All Ages, 2009-2029

Figure 3: 8MM, Diagnosed Prevalence (%) of T1D, Women, All Ages, 2009-2029

Figure 4: 8MM, Sources Used and Not Used, Diagnosed Prevalent Cases of T1D

Figure 5: 8MM, Sources Used, Diagnosed Prevalent Cases of T1D by BMI, Brittle Diabetes, Diabetic Ketoacidosis Event, and Hypoglycemia Events

Figure 6: 8MM, Sources Used, Total Prevalent Cases of T1D

Figure 7: 8MM, Diagnosed Prevalent Cases of T1D, All Ages, Both Sexes, N, 2019

Figure 8: 8MM, Age-Specific Diagnosed Prevalent Cases of T1D, Both Sexes, N, 2019

Figure 9: 8MM, Sex-Specific Diagnosed Prevalent Cases of T1D, All Ages, N, 2019

Figure 10: 8MM, Diagnosed Prevalent Cases of T1D by BMI, All Ages, N, 2019

Figure 11: 8MM, Diagnosed Prevalent Cases of T1D with Brittle Diabetes and Diabetic Ketoacidosis Events, All Ages, N, 2019

Figure 12: 8MM, Diagnosed Prevalent Cases of T1D Who Have Experienced Hypoglycemia Events, All Ages, N, 2019

Figure 13: 8MM, T1D Diagnosed Patients Who Are Eligible for Pancreas and/or Islet Transplantation and Who Require/Will Undergo a Kidney Transplant or Have Already Received a Kidney Transplant, All Ages, N, 2019

Figure 14: 8MM, Total Prevalent Cases of T1D, All Ages, Both Sexes, N, 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 20 7947 2745

Join our mailing list

Saved reports